<DOC>
	<DOCNO>NCT02124421</DOCNO>
	<brief_summary>Community hospital base phase II ( prospective randomize ) study evaluate toxicity cytoreductive surgery ( CRS ) hyperthermic intraperitoneal chemotherapy ( HIPEC ) newly diagnose , otherwise untreated , advanced stage ( stage III/IV ) epithelial ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Outcomes CRS/HIPEC Initial Treatment Ovarian , Fallopian Tube Primary Peritoneal Cancer</brief_title>
	<detailed_description>Primary endpoint : - To assess feasibility recruitment - Compare complication rate two study arm : CRS HIPEC CRS alone . Secondary endpoint : - To determine risk factor morbidity mortality - Assess completion rate 6 cycle systemic chemotherapy - To determine progression free survival 24 month - To determine overall survival 1 , 3 , 5 year - Evaluate health relate quality life Patients meet study criterion randomize one two treatment arm : 1 ) cytoreductive surgery ( CRS ) carboplatin-based hyperthermic intraperitoneal chemotherapy ( HIPEC ) follow IV combination chemotherapy carboplatin paclitaxel 2 ) cytoreductive surgery ( CRS ) alone follow adjuvant intraperitoneal ( IP ) IV chemotherapy combination cisplatin paclitaxel newly diagnose advanced stage ( stage III/IV ) ovarian , fallopian tube primary peritoneal cancer . Both study arm receive 6 cycle adjuvant chemotherapy . Twenty-four patient undergo CRS HIPEC perform surgical gynecologic oncologic surgeon Mercy Medical Center , follow systemic IV chemotherapy carboplatin ( AUC=6 ) paclitaxel ( 175mg/m2 ) 6 cycle postoperatively . Twenty-four patient undergo CRS perform surgical gynecologic oncologic surgeon Mercy Medical Center , follow IV/IP chemotherapy Day 1 : IV paclitaxel ( 135 mg/m2 ) , Day 2 : IP cisplatin ( 75 mg/m2 ) , Day 8 : IP paclitaxel ( 60 mg/m2 ) 6 cycle postoperatively .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Clinical presentation ovarian , fallopian tube primary peritoneal cancer Stage III/IV disease No prior treatment significant surgery management ovarian , fallopian tube , primary peritoneal carcinoma ; History laparoscopic procedure obtain diagnostic biopsy permit study Histological confirmation Eastern Cooperative Oncology Group performance status 02 Karnofsky performance status ≥ 70 % ≤1 cm residual disease completion cytoreductive surgery ( GOG criterion optimally cytoreduction ) Bone marrow function : 1 . Absolute neutrophil count ( ANC ) ≥1,000/mm3 2 . Platelets ≥100,000/mm3 3 . Hemoglobin ≥ 8.5 g/dL Renal function : 1 ) Creatinine ≤1.5 time upper limit normal calculated creatinine clearance ≥60ml/min Hepatic function : 1 . Bilirubin ≤1.5 time upper limit normal 2 . Alanine aminotransferase ( ALT ) ≤3 time upper limit normal 3 . Aspartate aminotransferase ( AST ) ≤3 time upper limit normal Blood coagulation parameter : 1 . Prothrombin time ( PT ) International Normalized Ratio ≤1.5 partial prothrombin time ( PTT ) ≤1.5 time upper limit normal 2 . For patient full dose warfarin , range International Normalized Ratio ( usually 2 3 ) 3 . Partial prothrombin time ( PTT ) &lt; 1.2 time upper limit normal 4 . Candidate administration postoperative standard platinumbased combination systemic chemotherapy ( adequate bone marrow , renal , hepatic function , blood coagulation parameter ) Any prior treatment modality diagnosis ovarian , fallopian tube , primary peritoneal cancerPrior surgical attempt cytoreductive surgery Stage I/II disease Presence invasive malignancy evidence cancer within past 3 year Known active acute hepatitis confirm diagnosis HIV Active systemic infection require use parenteral antibiotic History acute coronary syndrome ( ACS ) , within last 6 month , accord AHA definition New York Heart Association ( NYHA ) Class II higher congestive heart failure accord American Heart Association ( AHA ) definition Canadian Cardiovascular Society ( CCS ) Class II high angina grade accord AHA definition Uncontrolled hypertension define &gt; 140/90 clear surgery time consent cardiologist History cerebral artery disease prior stroke accord AHA definition last 6 month Renal insufficiency serum creatinine level ≥1.5 time upper limit normal calculated creatinine clearance &lt; 60 ml/min Patients concurrent severe medical problem unrelated malignancy preclude compliance study place unacceptable risk participation study determinate study investigator Pregnant woman exclude study carboplatin category D agent potential teratogenic effect . Due potential risk adverse event nurse infant secondary treatment mother carboplatin , breastfeed discontinue Life expectancy &lt; 12 week</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Cytoreductive surgery</keyword>
	<keyword>Hyperthermic Intraperitoneal chemotherapy</keyword>
	<keyword>Systemic chemotherapy</keyword>
	<keyword>Primary peritoneal carcinoma</keyword>
	<keyword>Fallopian Tube cancer</keyword>
	<keyword>Intraperitoneal chemotherapy</keyword>
	<keyword>IV/IP chemotherapy</keyword>
	<keyword>IV chemotherapy</keyword>
</DOC>